A research team has confirmed expectations of higher healthcare utilization and costs with relapsed Diffuse Large B-Cell Lymphoma (DLBCL).

Source: Economic burden of treatment for diffuse large b-cell lymphoma


David Cottle

UBB Owner & Administrator